Program
SYHA1813
A development code. Also written as “SYHA1813 oral solution (2.0g:25mg)” and “SYHA1813 oral solution (20ml:200mg)”.
Its studies are mostly in Meningioma, led by Shanghai Runshi Pharmaceutical Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Runshi Pharmaceutical Technology | 43 open or running | phase 3since May 18, 2026 | Nov 27, 2023 | Jan 31, 2027phase 2 · NCT06739213 |
- Named in cspc pharmaceutical group’s own pipeline as
SYHA1813
, phase 3, as of Aug 20, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2023First study: phase 1 study in Healthy ParticipantsFirst studyNCT06157918 · 19 enrolled · China
- Nov 8, 2024Phase 2 study in Unresectable Locally Advanced or Metastatic Solid TumorsNCT06682611 · 380 planned
- Dec 9, 2024Phase 2 study in RecurrenceNCT06739213 · 56 planned
- May 18, 2026Phase 3 study in High Grade MeningiomaPhase 3 reachedNCT07613450 · 136 planned
Ahead
- Nov 13, 2026Primary completion: phase 2 study in Unresectable Locally Advanced or Metastatic Solid TumorsNCT06682611
- Jan 31, 2027Primary completion: phase 2 study in RecurrenceNCT06739213
- Jul 31, 2029Primary completion: phase 3 study in High Grade MeningiomaNCT07613450
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07613450High Grade Meningioma | 3 | Not yet recruiting | Jul 31, 2029 | 136 |
| NCT06739213Recurrence | 2 | Not yet recruiting | Jan 31, 2027 | 56 |
| NCT06682611Unresectable Locally Advanced or Metastatic Solid Tumors | 2 | Not yet recruiting | Nov 13, 2026 | 380 |
| NCT06157918Healthy Participants · China | 1 | Completed | Jan 26, 2024 | 19 |
How it is read
Names in the registry
- “SYHA1813”, 3 entries
- “SYHA1813 oral solution (2.0g:25mg)”, 1 entry
- “SYHA1813 oral solution (20ml:200mg)”, 1 entry
Codes read as this program: SYHA1813.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.